Dan Cojocari, Ph.D. Email and Phone Number
Dan Cojocari, Ph.D. work email
- Valid
- Valid
Dan Cojocari, Ph.D. personal email
Oncology drug discovery and biomarkers scientist with a mission to bring better therapies to cancer patients.• Led biology of several oncology discovery projects that transitioned through early discovery that could bring first-in-class targeted drugs to cancer patients.• Contributing team member to clinical-stage programs ABBV-621 (Eftozanermin alfa TRAIL agonist), ABBV-467 (MCL-1 small molecule inhibitor), Mirzotamab clezutoclax (ABBV-155) .• Discovered the mechanism of action for the BCL2 inhibitor Venetoclax + HMA drug combination used in the treatment of AML.• Identified novel drug combinations for venetoclax in leukemia (pevonedistat), resulting in the initiation of two Phase I clinical trials, and uncovering mechanism of resistance using data from completed trials.• Previous research published in Nature Cell Biology, Nature Materials, Nature Protocols, Clinical Cancer Research and presented at numerous international conferences. A reviewer for several journals. Contributed to the development of the TRACER device published in Nature Materials/Protocols• PhD in cancer biology from University of Toronto at Princess Margaret Hospital focusing on tumour hypoxia, autophagy, UPR signaling. Active member of the American Association for Cancer Research and American Society of Hematology.While I have a connection to Amgen, opinions are my own and do not represent Amgen's position.
Abbvie
View- Website:
- abbvie.com
- Employees:
- 57013
- Company phone:
- + 0120-790-549
-
Senior Scientist Ii, Oncology Discovery, BiologyAbbvieLos Angeles, Ca, Us
-
Senior Scientist - Precision Medicine OncologyAmgen Nov 2023 - PresentThousand Oaks, Ca, UsPrecision Medicine, Oncology Discovery Biomarkers -
Senior Scientist Ii, Oncology Discovery, BiologyAbbvie Jul 2020 - Oct 2023North Chicago, Illinois, Us• Leading novel target biology for 2 programs by defining patient settings & understanding molecular determinants of activity; supporting small molecule and ADC programs.• Leading discovery program/clinical PD/biomarker assay development in-house and through CROs.• Progressing the discovery pipeline, associated translational/clinical research, and in-licensing activities while enhancing internal/external visibility.• Contributing team member for clinical-stage programs ABBV-621 (Eftozanermin alfa TRAIL agonist), ABBV-467 (MCL-1 small molecule inhibitor). • Managing a research team of 3 FTEs, including cross-site.
-
Senior Scientist I, Translational Oncology & BiomarkersAbbvie Sep 2017 - Jul 2020North Chicago, Illinois, UsPrecision Medicine venetoclax translational biology team.• Venetoclax development: generated experimental data to inform upon the mechanism of clinical activity with 5-Aza in AML, published in CCR journal (2020), and pevonedistat/5-Aza, published in Haematologica (2021)• Venetoclax development: advanced novel clinical concepts with emerging therapies, including establishing academic collaborations.• Led the implementation of a "clinic-to-bench" philosophy for oncology discovery apoptosis targets' biology efforts.• Managed and established new academic and industry project collaborations.
-
Postdoctoral Research FellowPrincess Margaret Cancer Centre Research Jan 2017 - Aug 2017Princess Margaret Cancer Center -
Doctoral Research FellowPrincess Margaret Cancer Centre Research Jan 2010 - Dec 2016Princess Margaret Cancer Center, Prof. Brad Wouters group http://www.wklab.org/• Published 6 original research manuscripts, 1 review article, including leading Nature journals.• $100,000 in university, provincial, and federal scholarships, and awards. cGPA: A• Selected to present work at 5 international conferences. Awarded travel funds.• Investigated the importance of the autophagy, UPR, antioxidant molecular pathways in pancreatic cancer cell survival in the hypoxic tumour microenvironment.
-
Summer Research AssistantUniversity Health Network May 2009 - Sep 2009Toronto, Ontario, CaRole of Rb in myogenic differentiation -
Senior Thesis InternLeslie Dan Faculty Of Pharmacy, University Of Toronto May 2008 - May 2009Toronto, Ontario, CaProf. Jeffrey Henderson laboratory. Suppression of Programed Cell Death regulators using lentiviral-mediated shRNA.
Dan Cojocari, Ph.D. Skills
Dan Cojocari, Ph.D. Education Details
-
University Of TorontoDep. Of Medical Biophysics -
University Of TorontoDep. Of Pharmaceutical Sciences
Frequently Asked Questions about Dan Cojocari, Ph.D.
What company does Dan Cojocari, Ph.D. work for?
Dan Cojocari, Ph.D. works for Abbvie
What is Dan Cojocari, Ph.D.'s role at the current company?
Dan Cojocari, Ph.D.'s current role is Senior Scientist II, Oncology Discovery, Biology.
What is Dan Cojocari, Ph.D.'s email address?
Dan Cojocari, Ph.D.'s email address is da****@****ott.com
What schools did Dan Cojocari, Ph.D. attend?
Dan Cojocari, Ph.D. attended University Of Toronto, University Of Toronto.
What skills is Dan Cojocari, Ph.D. known for?
Dan Cojocari, Ph.D. has skills like Leadership, Cancer Research, Collaborative Problem Solving, Reverse Transcription Polymerase Chain Reaction, Research And Development, Cell Biology, Xenografts, Elisa, Crispr, Western Blotting, Signal Transduction, Cell Signaling.
Who are Dan Cojocari, Ph.D.'s colleagues?
Dan Cojocari, Ph.D.'s colleagues are Remy Williams, Emma Elder, Simon Hanio, Nicole O'neil, Bs, Ccra, Zair Siham, Testing Mail, Maria P B Acoba.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial